or Try an Advanced Search...

    Neurocrine Biosciences Stocks List

    Symbol Grade Name % Change
    NBIX A Neurocrine Biosciences, Inc. -2.24
    SPRB F Spruce Biosciences, Inc. 3.37
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Alcohol Biopharmaceutical Cardiovascular Disease Clinical Development Congenital Adrenal Hyperplasia Diabetes Disorders Dyskinesia Endocrine Disorders Endometriosis Epilepsy Essential Tremor Ethers Fibroids Gnrh Antagonists Hormones Hyperplasia Insomnia Medicine Movement Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Neurocrine Biosciences stocks.

    Symbol Grade Name Weight
    PBE C PowerShares Dynamic Biotech & Genome 5.53
    IBRN C iShares Neuroscience and Healthcare ETF 5.08
    MNTL F Tema Neuroscience and Mental Health ETF 4.27
    FBT D First Trust Amex Biotech Index Fund 3.49
    JSMD C Janus Small/Mid Cap Growth Alpha ETF 3.27
    View all Neurocrine Biosciences ETFs...
    Compare ETFs
    Compare MNTL to FBT Compare MNTL to JSMD Compare PBE to FBT

        Neurocrine Biosciences Stocks Recent News

        Date Stock Title
        May 2 NBIX Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
        May 2 NBIX Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
        May 2 NBIX Q1 2024 Neurocrine Biosciences Inc Earnings Call
        May 2 NBIX Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements
        May 1 SPRB Spruce Biosciences to Participate in May Investor Conferences
        May 1 NBIX Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle
        May 1 NBIX Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
        May 1 NBIX Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
        May 1 NBIX Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 NBIX Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
        May 1 NBIX Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M
        May 1 NBIX Neurocrine Biosciences Reports First Quarter 2024 Financial Results
        Apr 30 NBIX UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
        Apr 30 NBIX Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
        Apr 30 SPRB Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
        Apr 30 NBIX Neurocrine Biosciences Q1 2024 Earnings Preview
        Apr 30 NBIX Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
        Related Industries: Biotechnology
        Related Stock Lists: Alcohol Biopharmaceutical Cardiovascular Disease Clinical Development Congenital Adrenal Hyperplasia Diabetes Disorders Dyskinesia Endocrine Disorders Endometriosis Epilepsy Essential Tremor Ethers Fibroids Gnrh Antagonists Hormones Hyperplasia Insomnia Medicine Movement Disorders
        Neurocrine Biosciences

        Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

        More about Neurocrine Biosciences
        Browse All Tags